Impact ledger
Adial Pharmaceuticals, Inc. (ADIL): the developments shaping its investment case
Follow the evidence affecting Adial Pharmaceuticals, Inc.'s valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Test assumptions, examine opportunities, and save your research.
Material developments
Evidence affecting valuation assumptions
Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.
| Date | Assumption | Direction | Interpretation |
|---|---|---|---|
| 2026-09-16 | share_count | Bullish | Automatic conversion of Series A Preferred Stock into 12,930,617 shares of Common Stock following stockholder vote. |
| 2026-09-16 | net_debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. |
| 2026-09-16 | interest_expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. |
| 2026-08-17 | multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. |
| 2026-08-17 | share_count | Bullish | Primary equity issuance increases diluted share count. |
| 2026-08-17 | share_count | Bullish | Stock component of consideration dilutes existing acquirer holders. |
| 2026-08-17 | net_debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. |
| 2026-08-17 | revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. |
Event impact log
3 events mapped to ADIL since 2026-08-17. Evidence through 2026-09-16.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-16 | Adial Pharmaceuticals, Inc. Amends PIPE and Note Exchange Agreements to Reclassify Warrant Liability | Direct financial restructuring improving balance sheet health and reducing potential future liabilities. | Bullish | 1-3m | 0.70 |
| 2026-08-17 | Adial Pharmaceuticals, Inc. Follow-On — $32M | Direct capital infusion and potential dilution from share issuance. The financing provides necessary capital for operations and the Azora acquisition, but the structure (private financing, note conversion) suggests potential for significant share count increase. | mixed | 1-3m | 0.80 |
| 2026-08-17 | Adial Pharmaceuticals Completed Acquisition of Azora Therapeutics | Direct acquisition of a new clinical-stage asset (AT177) for ulcerative colitis, diversifying pipeline beyond AD04. The non-cash R&D charge impacts near-term financials but the strategic value is long-term. | mixed | 1-5y | 0.70 |
Continue this research
Build your Adial Pharmaceuticals, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the ADIL entity page →